Indian Pharma in September 2025: Momentum, Disruption & Caution

By Anup Soans

October 8, 2025

By MedicinMan Editorial Team
Published: October 2025

💊 Introduction

September 2025 marked a turning point for India’s pharmaceutical industry. The market continued to grow in value despite regulatory tremors, safety controversies, and global trade pressures. On the brighter side, innovation and chronic-care therapies kept fueling demand, signaling long-term resilience.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Topics

Vivek V. Kamath Appointed CEO at PlasmaGen BioSciences

Pharma GCCs – What Used to Happen in Boston or Basel Now Happens in Bangalore

Indian Pharma in September 2025: Momentum, Disruption & Caution

💊 Introduction

Free Membership Required

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Anuj Pasrija Elevated to Country Lead, J&J MedTech India and Vice President – Surgery

China’s Biopharma Strategy: A Warning and Opportunity for India

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

Who Is Accountable for the Medicine in Your Hand?

Topics

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Anuj Pasrija Elevated to Country Lead, J&J MedTech India and Vice President – Surgery

China’s Biopharma Strategy: A Warning and Opportunity for India

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

Who Is Accountable for the Medicine in Your Hand?

Who Profits From Trust?

The Great Healthcare Dilemma: Who Will Own the Next Indian Hospital?

Indian Pharma’s Three Deficits—and Three Potential Dividends

Related Articles

What’s Killing Patients? Cancer or Rigged Drug Prices?

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Company

Headlines

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Anuj Pasrija Elevated to Country Lead, J&J MedTech India and Vice President – Surgery

China’s Biopharma Strategy: A Warning and Opportunity for India

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

Newsletter